Study on the Effects of Intraoperative Administration of Dexmedetomidine on the Prognosis and Survival Outcomes of Patients with Colorectal Cancer

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Oct 9

PMID 39381090

Authors

Chu Ren

Ying Zeng

Liuji Qiu

Dexing Luo

Junfang Wang

Xin Chen

Yan Yan

Affiliations

Soon will be listed here.

Abstract

Background: The perioperative period of tumor surgery commonly utilizes dexmedetomidine as an adjuvant analgesic for anesthesia. Nevertheless, there is a paucity of research investigating its influence on the prognosis of colorectal cancer (CRC). This article primarily aims to examine the correlation between the intraoperative administration of dexmedetomidine and recurrence-free survival (RFS) and overall survival (OS) of colorectal cancer patients, as well as its prognostic implications on survival.

Methods: According to the exclusion criteria, 76 patients undergoing laparoscopic radical resection of CRC under general anesthesia were enrolled at Huizhou Central People's Hospital in 2014. Kaplan-Meier method was used for univariate survival analysis of clinical prognostic factors, RFS, and OS in patients with CRC Cox regression analysis was used for multivariate survival analysis.

Results: A total of 76 patients with CRC were enrolled in this study. Among them, 36 patients were treated with dexmedetomidine (group D), and 40 patients were not treated with dexmedetomidine (group C) during the operation. Survival analysis showed that the RFS and OS of patients in group D were significantly higher than those in group C ( = 0.046 and = 0.021, respectively). Multivariate regression analysis demonstrated that the intraoperative administration of dexmedetomidine independently predicted a protective effect on OS = 0.025).

Conclusions: The intraoperative application of dexmedetomidine as an adjuvant analgesic has a protective effect on the prognosis and survival of patients with CRC and can improve the overall survival rate. Additionally, it influences the recurrence status of patients to a certain extent. These results suggest that dexmedetomidine significantly benefits on the long-term prognosis of patients with CRC.

References

Takahashi K, Yoshikawa Y, Kanda M, Hirata N, Yamakage M . Dexmedetomidine as a cardioprotective drug: a narrative review. J Anesth. 2023; 37(6):961-970. DOI: 10.1007/s00540-023-03261-w. View

Xiang H, Hu B, Li Z, Li J . Dexmedetomidine controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Inflammation. 2014; 37(5):1763-70. DOI: 10.1007/s10753-014-9906-1. View

Ramchandani A, Mihic-Gongora L, Hernandez R, Zafra-Poves M, Munoz M, Ferreira E . Psychological factors and prognostic communication preferences in advanced cancer: multicentre study. BMJ Support Palliat Care. 2023; 13(e3):e1342-e1350. DOI: 10.1136/spcare-2023-004221. View

Yao L, Zhai W, Jiang Z, He R, Xie W, Li Y . The Inhibitory Effects of Propofol on Colorectal Cancer Progression through the NF-κB/HIF-1α Signaling Pathway. Anticancer Agents Med Chem. 2024; 24(11):878-888. DOI: 10.2174/0118715206283884240326170501. View

Castillo L, Rivero E, Goffin V, Luthy I . Alpha-adrenoceptor agonists trigger prolactin signaling in breast cancer cells. Cell Signal. 2017; 34:76-85. DOI: 10.1016/j.cellsig.2017.03.003. View

Xia M, Ji N, Duan M, Tong J, Xu J, Zhang Y . Dexmedetomidine regulate the malignancy of breast cancer cells by activating α2-adrenoceptor/ERK signaling pathway. Eur Rev Med Pharmacol Sci. 2016; 20(16):3500-6. View

Ammar A, Mahmoud K, Kasemy Z, Helwa M . Cardiac and renal protective effects of dexmedetomidine in cardiac surgeries: A randomized controlled trial. Saudi J Anaesth. 2016; 10(4):395-401. PMC: 5044722. DOI: 10.4103/1658-354X.177340. View

Yang J, Wu Y, Xu Y, Jia J, Xi W, Deng H . Dexmedetomidine Resists Intestinal Ischemia-Reperfusion Injury by Inhibiting TLR4/MyD88/NF-κB Signaling. J Surg Res. 2020; 260:350-358. DOI: 10.1016/j.jss.2020.11.041. View

Liang S, Wang Y, Liu Y . Dexmedetomidine alleviates lung ischemia-reperfusion injury in rats by activating PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 2019; 23(1):370-377. DOI: 10.26355/eurrev_201901_16785. View

10.

Havidich J, Weiss J, Onega T, Low Y, Goodrich M, Davis M . The association of prescription opioid use with incident cancer: A Surveillance, Epidemiology, and End Results-Medicare population-based case-control study. Cancer. 2020; 127(10):1648-1657. DOI: 10.1002/cncr.33285. View

11.

Shin S, Kim K, Hwang H, Noh S, Oh J, Yoo Y . Immunomodulatory Effects of Perioperative Dexmedetomidine in Ovarian Cancer: An and Xenograft Mouse Model Study. Front Oncol. 2021; 11:722743. PMC: 8529066. DOI: 10.3389/fonc.2021.722743. View

12.

Chen P, Luo X, Dai G, Jiang Y, Luo Y, Peng S . Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. Exp Mol Med. 2020; 52(7):1062-1074. PMC: 8080602. DOI: 10.1038/s12276-020-0461-6. View

13.

Peng K, Shen Y, Ying Y, Kiaii B, Rodriguez V, Boyd D . Perioperative dexmedetomidine and 5-year survival in patients undergoing cardiac surgery. Br J Anaesth. 2021; 127(2):215-223. DOI: 10.1016/j.bja.2021.03.040. View

14.

Xu W, Zheng Y, Suo Z, Fei K, Wang Y, Liu C . Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trials. Front Oncol. 2022; 12:970557. PMC: 9518820. DOI: 10.3389/fonc.2022.970557. View

15.

Zhou L, Li J, Liu X, Tang Y, Li T, Deng H . Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a/EGR1 axis. Cell Death Discov. 2022; 8(1):31. PMC: 8770558. DOI: 10.1038/s41420-021-00805-5. View

16.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

17.

Zhang Q, Liu X, Hu Q, Liu Z, Liu Z, Zhang H . Dexmedetomidine inhibits mitochondria damage and apoptosis of enteric glial cells in experimental intestinal ischemia/reperfusion injury via SIRT3-dependent PINK1/HDAC3/p53 pathway. J Transl Med. 2021; 19(1):463. PMC: 8588684. DOI: 10.1186/s12967-021-03027-6. View

18.

Sun W, Li F, Wang X, Liu H, Mo H, Pan D . Effects of Dexmedetomidine on Patients Undergoing Laparoscopic Surgery for Colorectal Cancer. J Surg Res. 2021; 267:687-694. DOI: 10.1016/j.jss.2021.06.043. View

19.

Liu J, Pan S . Protective effects of estrogen combined with sevoflurane in an experimental model of cerebral infarction and focal cerebral ischemia-reperfusion injury. Eur Rev Med Pharmacol Sci. 2016; 20(9):1839-44. View

20.

Nie Y, Liu Y, Luo Q, Huang S . Effect of dexmedetomidine combined with sufentanil for post-caesarean section intravenous analgesia: a randomised, placebo-controlled study. Eur J Anaesthesiol. 2014; 31(4):197-203. DOI: 10.1097/EJA.0000000000000011. View